keyword
MENU ▼
Read by QxMD icon Read
search

glatiramer acetate

keyword
https://www.readbyqxmd.com/read/29663814/new-biological-agents-in-the-treatment-of-multiple-sclerosis
#1
M Buc
Multiple sclerosis (MS) is an inflammatory disease induced by autoimmune processes. Their understanding has resulted in an introduction of biological agents to its treatment. Interferon beta and glatiramer acetate have been in clinical practice for more than 20 years. Nowadays, novel biologics, which target molecules involved in immunopathological processes more specifically have entered the scene. They are represented by monoclonal antibodies binding to molecules VLA4 (natalizumab), CD20 (ocrelizumab), CD52 (alemtuzumab) or alpha subunit of IL-2 receptor (daclizumab) or by small molecules such as those modulating the receptors involved in regulation of lymphocyte migration (fingolimod, ozanimod) or in induction of lymphopenia by apoptosis (dimethyl fumarate, cladribine)...
2018: Bratislavské Lekárske Listy
https://www.readbyqxmd.com/read/29652301/-the-results-of-an-open-comparative-retrospective-trial-of-the-course-of-multiple-sclerosis-during-treatment-with-infibeta-and-other-interferon-beta-bioanalogues-and-glatiramer-acetate
#2
F A Khabirov, T I Khaybullin, E V Granatov, S R Shakirzianova, N N Babicheva, O S Kochergina, E F Rakhmatullina, G M Akhmedova, L A Averyanova, M A Yakupov, Zh F Sabirov
AIM: To evaluate the efficacy and safety of the interferon beta-1b bioanalogue 'infibeta' in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. MATERIAL AND METHODS: The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29643001/immune-cell-bdnf-expression-in-treatment-na%C3%A3-ve-relapsing-remitting-multiple-sclerosis-patients-and-following-one-year-of-immunomodulation-therapy
#3
Alicja Kalinowska-Łyszczarz, Mikołaj A Pawlak, Aleksandra Wyciszkiewicz, Krystyna Osztynowicz, Wojciech Kozubski, Sławomir Michalak
Although neurons are the main source of neurotrophins in the healthy brain, neurotrophins can also be expressed in the immune system. We have previously shown that in relapsing-remitting multiple sclerosis (RRMS) lower immune-cell neurotrophin levels are associated with brain atrophy and cognitive impairment. The aim of the present study was to assess if immune-cell neurotrophin expression is impaired in MS as compared with the healthy controls, and to describe if these levels change in treatment-naïve RRMS patients, following one year of immunomodulation...
March 29, 2018: Neurologia i Neurochirurgia Polska
https://www.readbyqxmd.com/read/29602795/disease-modifying-drugs-for-multiple-sclerosis-and-infection-risk-a-cohort-study
#4
José Maria Andreas Wijnands, Feng Zhu, Elaine Kingwell, John David Fisk, Charity Evans, Ruth Ann Marrie, Yinshan Zhao, Helen Tremlett
OBJECTIVE: Little is known about disease-modifying treatments (DMTs) for multiple sclerosis (MS) and infection risk in clinical practice. We examined the association between DMTs and infection-related medical encounters. METHODS: Using population-based administrative data from British Columbia, Canada, we identified MS cases and followed them from their first demyelinating event (1996-2013) until emigration, death or study end (December 2013). Associations between DMT exposure (by DMT generation or class) and infection-related physician or hospital claims were assessed using recurrent time-to-events models, adjusted for age, sex, socioeconomic status, index year and comorbidity count...
March 30, 2018: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/29571854/effect-of-switching-from-glatiramer-acetate-20-mg-daily-to-glatiramer-acetate-40-mg-three-times-a-week-on-gray-and-white-matter-pathology-in-subjects-with-relapsing-multiple-sclerosis-a-longitudinal-dti-study
#5
Robert Zivadinov, Niels Bergsland, Jesper Hagemeier, Eleonora Tavazzi, Deepa P Ramasamy, Jackie Durfee, Mariya Cherneva, Ellen Carl, Jillian Carl, Channa Kolb, David Hojnacki, Bianca Weinstock-Guttman
BACKGROUND: Glatiramer acetate (GA) 40 mg × 3/weekly was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). While the beneficial effect of GA 20 mg/daily in MS patients on non-conventional MRI measures has been demonstrated, the effect of GA 40 mg × 3/weekly at the microstructural tissue level has yet to be explored. OBJECTIVE: To investigate the effect of switching from GA 20 mg/daily to GA 40 mg × 3/weekly on the evolution of microstructural changes in the thalamus and normal appearing white matter (NAWM), using diffusion tensor imaging (DTI)...
April 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/29526318/a-comparative-study-of-melatonin-and-immunomodulatory-therapy-with-interferon-beta-and-glatiramer-acetate-in-a-mouse-model-of-multiple-sclerosis
#6
E J Ramos González, L J Ramirez Jirano, D Z García Martínez, G G Ortiz, L F Jave Suárez, C A Leal Cortes, O K Bitzer Quintero
INTRODUCTION: Multiple sclerosis (MS) is a chronic, demyelinating, autoimmune disease of the central nervous system causing neuroinflammation. Experimental autoimmune encephalitis (EAE) is a model of the disease. MS is classically treated with interferon beta (IFN-β) and glatiramer acetate (GA). Melatonin (MLT) has been reported to modulate immune system responses. The aim of the present study is to analyse the effects of MLT administration in comparison with the first-line treatments for MS (IFN-β and GA)...
March 8, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29526118/first-line-disease-modifying-drugs-in-relapsing-remitting-multiple-sclerosis-an-italian-real-life-multicenter-study-on-persistence
#7
Diana Ferraro, Valentina Camera, Eleonora Baldi, Veria Vacchiano, Erica Curti, Angelica Guareschi, Susanna Malagù, Sara Montepietra, Silvia Strumia, Mario Santangelo, Luisa Caniatti, Matteo Foschi, Alessandra Lugaresi, Franco Granella, Ilaria Pesci, Luisa Motti, Walter Neri, Paolo Immovilli, Enrico Montanari, Francesca Vitetta, Anna Maria Simone, Patrizia Sola
OBJECTIVE: The introduction of oral disease-modifying drugs (DMDs) in addition to the available, injectable, ones for Relapsing-Remitting Multiple Sclerosis (RRMS) could be expected to improve medication persistence due to a greater acceptability of the route of administration. Aim of the study was to compare the proportion of patients discontinuing injectable DMDs (interferon beta 1a/1b, pegylated interferon, glatiramer acetate) with those discontinuing oral DMDs (dimethylfumarate and teriflunomide) during an observation period of at least 12 months...
March 10, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29523094/pediatric-multiple-sclerosis-a-review
#8
Raed Alroughani, Alexey Boyko
BACKGROUND: Pediatric-onset multiple sclerosis (POMS) prevalence and incidence rates are increasing globally. No disease-modifying therapy are approved for MS pediatric population. Hence, we aim to review the literature on POMS to guide treating physicians on the current understanding of diagnosis and management of pediatric MS. METHODS: The authors performed a literature search and reviewed the current understanding on risk factors and disease parameters in order to discuss the challenges in assessing and implementing diagnosis and therapy in clinical practice...
March 9, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29521113/lateral-switch-to-ifn-beta-1a-44-mcg-may-be-effective-as-escalation-switch-to-fingolimod-in-selected-persons-with-relapsing-remitting-multiple-sclerosis-a-real-world-setting-experience
#9
E D'Amico, F Patti, A Zanghì, S Lo Fermo, C G Chisari, M Zappia
BACKGROUND: The efficacy of lateral and escalation switch is a challenge in MS. We compared in a real-world setting the efficacy of switching to IFN beta-1a 44 mcg or to fingolimod in persons with relapsing remitting MS (pwRRMS) who failed with others injectable IFNs or glatiramer acetate. RESEARCH DESIGN AND METHODS: retrospective analysis of 24 months prospectively-collected data at the MS center of the University of Catania, Italy was performed. Patients who were switched to IFN-beta 1a 44 mcg or fingolimod were analyzed using propensity-score covariate adjustment model within demographic (e...
March 9, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29507538/pregnancy-outcomes-from-the-branded-glatiramer-acetate-pregnancy-database
#10
Magnhild Sandberg-Wollheim, Orit Neudorfer, Augusto Grinspan, Bianca Weinstock-Guttman, Judith Haas, Guillermo Izquierdo, Claire Riley, Amy Perrin Ross, Peleg Baruch, Talya Drillman, Patricia K Coyle
Background: Appropriate counseling and treatment for women with multiple sclerosis (MS) who may become pregnant requires an understanding of the effects of exposure to disease-modifying therapies (DMTs) during pregnancy. Current reports and studies are limited in their usefulness, mostly by small sample size. Branded glatiramer acetate (GA) is a DMT approved for the treatment of relapsing forms of MS. For more than 2 decades, it has been shown to be efficacious and to have a favorable safety profile...
January 2018: International Journal of MS Care
https://www.readbyqxmd.com/read/29484976/new-life-to-an-old-treatment-pegylated-interferon-beta-1a-in-the-management-of-multiple-sclerosis
#11
Miguel Angel Ortiz, Laura Espino-Paisan, Concepcion Nunez, Roberto Alvarez-Lafuente, Elena Urcelay
In the 1990s, the betainterferons and glatiramer acetate were introduced for treating relapsing-remitting multiple sclerosis. These medications have a demonstrated record of efficacy and safety, although they require frequent administration via injection and are only partially effective. The optimization of treatment in patients who do not respond adequately to this first-line therapy is essential for attaining the best long-term outcomes. Switching to the recently approved emergent therapies is a strategy to consider for treatment of patients with a suboptimal response...
February 25, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29464673/comparison-of-disease-modifying-therapies-for-the-management-of-multiple-sclerosis-analysis-of-healthcare-resource-utilization-and-relapse-rates-from-us-insurance-claims-data
#12
Jacqueline Nicholas, Aaron Boster, Ning Wu, Wei-Shi Yeh, Monica Fay, Jon Kendter, Ming-Yi Huang, Andrew Lee
BACKGROUND: Data on comparative healthcare resource utilization and costs associated with the newer oral disease-modifying therapies (DMTs) for managing relapsing-remitting multiple sclerosis (MS) in routine clinical practice are limited. The purpose of this study was to estimate healthcare resource utilization, costs, and relapse rates in the year after initiating treatment with dimethyl fumarate (DMF), interferon (IFN)-β, glatiramer acetate (GA), teriflunomide, or fingolimod in routine clinical practice for patients with MS who did not receive a DMT in the previous year...
March 2018: PharmacoEconomics open
https://www.readbyqxmd.com/read/29440323/the-evolving-mechanisms-of-action-of-glatiramer-acetate
#13
Thomas Prod'homme, Scott S Zamvil
Glatiramer acetate (GA) is a synthetic amino acid copolymer that is approved for treatment of relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS). GA reduces multiple sclerosis (MS) disease activity and has shown comparable efficacy with high-dose interferon-β. The mechanism of action (MOA) of GA has long been an enigma. Originally, it was recognized that GA treatment promoted expansion of GA-reactive T-helper 2 and regulatory T cells, and induced the release of neurotrophic factors...
February 12, 2018: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/29424049/astrocyte-disruption-of-neurovascular-communication-is-linked-to-cortical-damage-in-an-animal-model-of-multiple-sclerosis
#14
Raya Eilam, Menahem Segal, Rafael Malach, Michael Sela, Ruth Arnon, Rina Aharoni
To elucidate mechanisms contributing to cortical pathology in multiple sclerosis (MS), we investigated neurovascular aberrations, in particular the association of astrocytes with cortical neurons and blood vessels, in mice induced with experimental autoimmune encephalomyelitis (EAE). Blood-brain barrier (BBB) dysfunction was evident by leakage of the tracer sodium fluorescein, along with reduced expression of claudin-5 by endothelial cells and desmin by pericytes. Immunohistological and ultrastructural analyses revealed detachment of the astroglial cell bodies from the blood vessels and loss of their connections with both the blood vessels and the neuronal synapses...
February 9, 2018: Glia
https://www.readbyqxmd.com/read/29417493/depression-in-multiple-sclerosis-epidemiology-aetiology-diagnosis-and-treatment
#15
REVIEW
Claudio Solaro, Giulia Gamberini, Fabio Giuseppe Masuccio
Depressive disorders are common in patients with multiple sclerosis, influencing their quality of life and adherence to treatments, as well as becoming more frequent with the progression of the disease and in the secondary progressive form of multiple sclerosis. Patients with multiple sclerosis often experience a typical cluster of symptoms in association with depression, such as fatigue, pain and cognitive impairment. However, the pathogenesis of multiple sclerosis-related depression remains partially unclear, even though genetic, immune-inflammatory and psychosocial factors might be seen to play a role, in addition to the brain structural alterations documented by magnetic resonance imaging studies...
February 7, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29362931/immunoregulation-of-theiler-s-virus-induced-demyelinating-disease-by-glatiramer-acetate-without-suppression-of-antiviral-immune-responses
#16
Seiichi Omura, Fumitaka Sato, Nicholas E Martinez, Tierra Range, Lesya Ekshyyan, Alireza Minagar, J Steven Alexander, Ikuo Tsunoda
While most disease-modifying drugs (DMDs) regulate multiple sclerosis (MS) by suppressing inflammation, they can potentially suppress antiviral immunity, causing progressive multifocal leukoencephalopathy (PML). The DMD glatiramer acetate (GA) has been used for MS patients who are at high risk of PML. We investigated whether GA is safe for use in viral infections by using a model of MS induced by infection with Theiler's murine encephalomyelitis virus (TMEV). Treatment of TMEV-infected mice with GA neither enhanced viral loads nor suppressed antiviral immune responses, while it resulted in an increase in the Foxp3/Il17a ratio and IL-4/IL-10 production...
May 2018: Archives of Virology
https://www.readbyqxmd.com/read/29356977/short-and-long-term-clinical-outcomes-of-use-of-beta-interferon-or-glatiramer-acetate-for-people-with-clinically-isolated-syndrome-a-systematic-review-of-randomised-controlled-trials-and-network-meta-analysis
#17
REVIEW
X Armoiry, A Kan, G J Melendez-Torres, R Court, P Sutcliffe, P Auguste, J Madan, C Counsell, A Clarke
BACKGROUND: Beta-interferon (IFN-β) and glatiramer acetate (GA) have been evaluated in people with clinically isolated syndrome (CIS) with the aim to delay a second clinical attack and a diagnosis of clinically definite multiple sclerosis (CDMS). We systematically reviewed trials evaluating the short- and long-term clinical effectiveness of these drugs in CIS. METHODS: We searched multiple electronic databases. We selected randomised controlled studies (RCTs) conducted in CIS patients and where the interventions were IFN-β and GA...
January 22, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29356206/survey-of-diagnostic-and-treatment-practices-for-multiple-sclerosis-ms-in-europe-part-2-progressive-ms-paediatric-ms-pregnancy-and-general-management
#18
O Fernández, M Delvecchio, G Edan, S Fredrikson, G Giovannoni, H-P Hartung, E Havrdova, L Kappos, C Pozzilli, P S Soerensen, B Tackenberg, P Vermersch, G Comi
BACKGROUND AND PURPOSE: The European Charcot Foundation supported the development of a set of surveys to understand current practice patterns for the diagnosis and management of multiple sclerosis (MS) in Europe. Part 2 of the report summarizes survey results related to secondary progressive MS (SPMS), primary progressive MS (PPMS), pregnancy, paediatric MS and overall patient management. METHODS: A steering committee of MS neurologists developed case- and practice-based questions for two sequential surveys distributed to MS neurologists throughout Europe...
May 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29332426/effects-of-multiple-sclerosis-and-medications-on-menopausal-age
#19
Ülkü Türk Börü, Cansu Köseoğlu Toksoy, Cem Bölük, Adnan Bilgiç, Mustafa Taşdemir
Objectives We aimed to determine whether multiple sclerosis (MS) and methylprednisolone and disease-modifying drugs have an effect on menopausal age. Methods A total of 86 patients and 98 healthy subjects were included in this study. The natural menopausal age of the patients and healthy subjects were compared. The cumulative dosages of methylprednisolone, beta interferons (IFNβs), and glatiramer acetate were calculated. The effects of the Expanded Disability Status Scale (EDSS), duration of the disease, and cumulative dosage of medications on menopausal age were evaluated...
March 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29305608/disease-course-and-treatment-responses-in-children-with-relapsing-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease
#20
Yael Hacohen, Yu Yi Wong, Christian Lechner, Maciej Jurynczyk, Sukhvir Wright, Bahadir Konuskan, Judith Kalser, Anne Lise Poulat, Helene Maurey, Esther Ganelin-Cohen, Evangeline Wassmer, Chery Hemingway, Rob Forsyth, Eva Maria Hennes, M Isabel Leite, Olga Ciccarelli, Banu Anlar, Rogier Hintzen, Romain Marignier, Jacqueline Palace, Matthias Baumann, Kevin Rostásy, Rinze Neuteboom, Kumaran Deiva, Ming Lim
Importance: Myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) are consistently identified in a range of demyelinating disorders in adults and children. Current therapeutic strategies are largely center specific, and no treatments have been formally evaluated. Objective: To examine the clinical phenotypes, treatment responses, and outcomes of children with relapsing MOG-Ab-associated disease. Design, Setting, and Participants: This study prospectively collected demographic, clinical, and radiologic data from 102 patients from 8 countries of the EU Paediatric Demyelinating Disease Consortium from January 1, 2014, through December 31, 2016...
April 1, 2018: JAMA Neurology
keyword
keyword
80154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"